Literature DB >> 25805751

Proton-Pump Inhibitor Exposure Aggravates Clostridium difficile-Associated Colitis: Evidence From a Mouse Model.

Yuan-Pin Hung1, Wen-Chien Ko2, Po-Han Chou3, Yi-Hsuan Chen3, Hsiao-Ju Lin1, Ya-Hui Liu3, Hung-Wen Tsai4, Jen-Chieh Lee5, Pei-Jane Tsai6.   

Abstract

BACKGROUND: Clostridium difficile is currently the leading cause of infectious diarrhea in hospitalized patients. In addition to the infection due to toxigenic C. difficile in the gastrointestinal tract of susceptible hosts, other predisposing factors for C. difficile infection (CDI) are identified, including advanced age, a prolonged hospital stay, and use of acid-suppressive drugs. Of note, exposure to gastric acid-reducing agents, such as H2 blockers and proton pump inhibitors (PPIs), remains a controversial risk factor, and has been associated with CDI in some studies but not in others. A mouse model of antibiotic-associated clostridial colitis was established to examine the role of PPIs for CDI.
MATERIALS AND METHODS: A mouse model of antibiotic-associated clostridial colitis was set up. NF-κB reporter mice were used to address the in vivo spatial and temporal inflammatory patterns of C. difficile-associated colitis. Serum levels of lipopolysaccharide and dextran-FITC were measured to reflect the barrier permeability of affected intestines.
RESULTS: Mice with CDI that were exposed to PPI exhibited greater losses of stool consistency and body and cecal weights than those that were not exposed to PPI. Further, more neutrophilic infiltrations, epithelial damage, and inflammatory cytokine expression were noted in colon specimens of the mice with PPI exposure. More-evident inflammatory responses were detected by in vivo imaging of NF-κB reporter mice with CDI that were exposed to PPI. Gut barrier permeability was increased to a greater extent, as reflected by higher serum levels of lipopolysaccharide and dextran-FITC in mice with CDI that were exposed to PPI.
CONCLUSIONS: Our mouse model demonstrates that PPI exposure increases the severity of intestinal inflammation in mice with C. difficile-associated colitis.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  C. difficile infection; NF-κB reporter mice; gut barrier permeability; mouse model; proton-pump inhibitor

Mesh:

Substances:

Year:  2015        PMID: 25805751     DOI: 10.1093/infdis/jiv184

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  Clostridium difficile Infection: An Epidemiology Update.

Authors:  Ana C De Roo; Scott E Regenbogen
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

2.  Intestinal epithelial PKM2 serves as a safeguard against experimental colitis via activating β-catenin signaling.

Authors:  Xinlei Sun; Li Yao; Hongwei Liang; Dong Wang; Yueqin He; Yao Wei; Lei Ye; Kai Wang; Limin Li; Jiangning Chen; Chen-Yu Zhang; Guifang Xu; Fangyu Wang; Ke Zen
Journal:  Mucosal Immunol       Date:  2019-08-28       Impact factor: 7.313

3.  Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model.

Authors:  Yi-Wen Liu; Yu-Hung Chen; Jenn-Wei Chen; Pei-Jane Tsai; I-Hsiu Huang
Journal:  Front Microbiol       Date:  2017-07-25       Impact factor: 5.640

4.  Octahedron Iron Oxide Nanocrystals Prohibited Clostridium difficile Spore Germination and Attenuated Local and Systemic Inflammation.

Authors:  Wei-Ting Lee; Ya-Na Wu; Yi-Hsuan Chen; Shang-Rung Wu; Tsai-Miao Shih; Tsung-Ju Li; Li-Xing Yang; Chen-Sheng Yeh; Pei-Jane Tsai; Dar-Bin Shieh
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

5.  Proton pump inhibitor induced collagen expression in colonocytes is associated with collagenous colitis.

Authors:  Shiori Mori; Yui Kadochi; Yi Luo; Rina Fujiwara-Tani; Yukiko Nishiguchi; Shingo Kishi; Kiyomu Fujii; Hitoshi Ohmori; Hiroki Kuniyasu
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

6.  Risk factors for Clostridium difficile infection in surgical patients hospitalized in a tertiary hospital in Belgrade, Serbia: a case-control study.

Authors:  Vesna Šuljagić; Ivan Miljković; Srđan Starčević; Nenad Stepić; Zoran Kostić; Dragutin Jovanović; Jelena Brusić-Renaud; Biljana Mijović; Sandra Šipetić-Grujičić
Journal:  Antimicrob Resist Infect Control       Date:  2017-03-27       Impact factor: 4.887

7.  Vancomycin-Loaded Nanoparticles Enhance Sporicidal and Antibacterial Efficacy for Clostridium difficile Infection.

Authors:  Yi-Hsuan Chen; Tsung-Ju Li; Bo-Yang Tsai; Liang-Kuei Chen; Yi-Hsin Lai; Meng-Jia Li; Cheng-Yang Tsai; Pei-Jane Tsai; Dar-Bin Shieh
Journal:  Front Microbiol       Date:  2019-05-24       Impact factor: 5.640

8.  The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model.

Authors:  Sarah Tomkovich; Nicholas A Lesniak; Yuan Li; Lucas Bishop; Madison J Fitzgerald; Patrick D Schloss
Journal:  mSphere       Date:  2019-11-20       Impact factor: 4.389

9.  The Transcriptional Regulator Lrp Contributes to Toxin Expression, Sporulation, and Swimming Motility in Clostridium difficile.

Authors:  Kuan-Yu Chen; Jagat Rathod; Yi-Ching Chiu; Jenn-Wei Chen; Pei-Jane Tsai; I-Hsiu Huang
Journal:  Front Cell Infect Microbiol       Date:  2019-10-17       Impact factor: 5.293

10.  Lauric Acid Is an Inhibitor of Clostridium difficile Growth in Vitro and Reduces Inflammation in a Mouse Infection Model.

Authors:  Hsiao-Ting Yang; Jenn-Wei Chen; Jagat Rathod; Yu-Zhen Jiang; Pei-Jane Tsai; Yuan-Pin Hung; Wen-Chien Ko; Daniel Paredes-Sabja; I-Hsiu Huang
Journal:  Front Microbiol       Date:  2018-01-17       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.